GTS Securities’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-81,500
Closed -$9.37M – 3156
2024
Q3
$9.37M Buy
81,500
+47,900
+143% +$5.44M 0.02% 540
2024
Q2
$3.58M Sell
33,600
-2,300
-6% -$231K 0.01% 1087
2024
Q1
$3.47M Sell
35,900
-44,800
-56% -$4.59M 0.01% 1100
2023
Q4
$8.15M Sell
80,700
-13,800
-15% -$1.33M 0.01% 713
2023
Q3
$9.63M Buy
+94,500
New +$9.59M 0.02% 619

Other funds holding NVS

GTS Securities's NVS Position: Q2 2026 in Review

GTS Securities opened a new position in Novartis (NVS) in Q2 2026: 3,897 shares worth $611K. The stake represents 0.01% of the portfolio and ranks #628 among its holdings. This is a return to the name: GTS Securities previously reported a position in NVS as recently as Q4 2025.

GTS Securities first reported a position in NVS in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.6M in Q3 2025. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • GTS Securities held 3,897 shares of Novartis worth $611K as of Q2 2026.
  • Novartis was a new GTS Securities position in Q2 2026.
  • Novartis made up 0.01% of GTS Securities's portfolio in Q2 2026, its #628 holding.
  • GTS Securities first reported a position in Novartis in Q3 2024 and has held it in 7 quarters since.
  • GTS Securities's Novartis position peaked at $1.6M in Q3 2025.
  • 1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.